Syngene tests investor appetite for IPO

Parent Biocon hopes the CRO's strong growth profile and expansion plans will mitigate recent downturn in the Indian equity market

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES